We demonstrate that the genetic knockout of PHD2/3 in activated CD8 T cells prior to adoptive cell transfer significantly improves their survival and efficacy in inhibiting tumor growth in vivo, across a range of tumor models. Here, EGLN1 is linked to neoplasm.